Q2 EPS Estimates for Nuvectis Pharma Increased by Analyst

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Equities research analysts at HC Wainwright lifted their Q2 2025 earnings estimates for shares of Nuvectis Pharma in a research report issued to clients and investors on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.28) for the quarter, up from their prior forecast of ($0.31). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.11) EPS, FY2026 earnings at ($1.40) EPS, FY2027 earnings at ($1.60) EPS and FY2028 earnings at ($1.90) EPS.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.03.

Other equities analysts also recently issued reports about the stock. Laidlaw started coverage on shares of Nuvectis Pharma in a report on Monday, March 17th. They set a “buy” rating and a $19.00 price target on the stock. Maxim Group began coverage on Nuvectis Pharma in a research note on Wednesday, April 2nd. They set a “buy” rating and a $17.00 target price on the stock.

Nuvectis Pharma Price Performance

Shares of NVCT stock opened at $8.99 on Friday. The company has a market cap of $212.48 million, a PE ratio of -7.75 and a beta of -0.11. Nuvectis Pharma has a 1 year low of $4.44 and a 1 year high of $11.80. The stock’s 50 day simple moving average is $8.99 and its two-hundred day simple moving average is $7.22.

Hedge Funds Weigh In On Nuvectis Pharma

A number of hedge funds have recently made changes to their positions in the company. Baldwin Wealth Partners LLC MA raised its position in shares of Nuvectis Pharma by 0.7% in the first quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company’s stock valued at $3,502,000 after buying an additional 2,500 shares during the last quarter. Iridian Asset Management LLC CT purchased a new stake in shares of Nuvectis Pharma in the first quarter valued at approximately $2,481,000. Marshall Wace LLP increased its holdings in shares of Nuvectis Pharma by 191.0% in the fourth quarter. Marshall Wace LLP now owns 124,571 shares of the company’s stock valued at $674,000 after purchasing an additional 81,757 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Nuvectis Pharma by 49.8% in the third quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock valued at $501,000 after purchasing an additional 26,489 shares during the last quarter. Finally, Forbes J M & Co. LLP lifted its position in Nuvectis Pharma by 21.9% during the fourth quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company’s stock worth $319,000 after buying an additional 10,599 shares in the last quarter. Institutional investors and hedge funds own 96.77% of the company’s stock.

Insider Buying and Selling at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri bought 12,444 shares of the firm’s stock in a transaction that occurred on Tuesday, May 6th. The stock was purchased at an average cost of $8.59 per share, for a total transaction of $106,893.96. Following the purchase, the insider now directly owns 2,896,565 shares in the company, valued at approximately $24,881,493.35. This trade represents a 0.43 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 35.78% of the stock is currently owned by company insiders.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.